Vaginal Cancer Treatment in India and UAE | Complete Patient Guide

• Confirmed histopathologic diagnosis of vaginal carcinoma (SCC, adenocarcinoma, or other histology) on colposcopy-directed biopsy or EUA biopsy

• FIGO Stage I–IVA disease being considered for curative-intent treatment; Stage IVB patients evaluated for palliative or systemic protocols

• ECOG Performance Status 0–2 (sufficient functional reserve for surgery or chemoradiation)

• Adequate bone marrow reserve: ANC ≥1,500/µL, platelets ≥100,000/µL, hemoglobin ≥9 g/dL (for cisplatin eligibility)

• Adequate renal function: GFR ≥50 mL/min (creatinine clearance assessed before platinum-based chemotherapy)

• No prior pelvic irradiation exceeding tolerance doses (prior RT history requires brachytherapy dose optimization and is a relative contraindication to further EBRT)

• HPV genotyping and PD-L1 expression / MSI/MMR status testing for systemic therapy eligibility (pembrolizumab in PD-L1 CPS ≥10 or MSI-H/dMMR tumors)

• Required pre-treatment diagnostics: MRI pelvis with contrast (tumor volumetry and parametrial assessment), PET-CT whole body (nodal and distant metastasis staging), colposcopy ± cervical biopsy (to exclude primary cervical cancer), cystoscopy and proctoscopy (if Stage III–IVA), CBC, CMP, LFTs, CA-125, SCC antigen, HIV serology, HPV genotype panel

• Contraindications to surgery: prior extensive pelvic surgery with hostile pelvis, unresectable parametrial disease, significant cardiopulmonary comorbidity precluding general anesthesia (ASA Class IV), patient refusal of surgical intervention

• Contraindications to concurrent cisplatin: GFR <50 mL/min, pre-existing grade ≥2 peripheral neuropathy, cisplatin allergy (carboplatin substitution protocol available)

• Relative contraindications to brachytherapy: prior pelvic irradiation at/near tolerance, active pelvic infection, severe vaginal stenosis precluding applicator placement

SURGICAL APPROACHES

Radical Vaginectomy: Indicated for Stage I upper-vaginal SCC in patients without prior irradiation. En-bloc resection of the vagina with adequate margins (≥1 cm), often combined with pelvic lymph node dissection (sentinel node biopsy increasingly utilized). Vaginal reconstruction using split-thickness skin grafts, Singapore (pudendal thigh) flaps, or gracilis myocutaneous flaps is performed concurrently by reconstructive surgeons to preserve sexual function.

Robotic-Assisted Radical Vaginectomy + Pelvic Lymphadenectomy (da Vinci Xi Platform): Available at select high-volume centers in India (Tata Memorial, Apollo, Manipal) and UAE (Cleveland Clinic Abu Dhabi, Mediclinic City). Offers 10× magnified 3D visualization, wristed instrumentation enabling precise dissection in the narrow bony pelvis, reduced blood loss (mean 150–200 mL vs. 400–600 mL open), shorter hospitalization, and faster return to ambulation. Particularly advantageous for upper-vaginal tumors near the bladder trigone.

Pelvic Exenteration: Reserved for recurrent or persistent central disease after prior chemoradiation. Anterior exenteration (bladder + vagina), posterior exenteration (rectum + vagina), or total pelvic exenteration depending on organ involvement. Requires ileal conduit or neobladder reconstruction and colostomy where applicable. Performed by multidisciplinary surgical teams.

CONCURRENT CHEMORADIATION (DEFINITIVE — FIRST-LINE FOR MOST PATIENTS)

External Beam Radiotherapy (EBRT): Delivered using IMRT or VMAT to the primary tumor, whole pelvis, and involved lymph node regions. Total dose: 45–50.4 Gy in 25–28 fractions over 5–6 weeks. IMRT significantly reduces dose to bladder, rectum, and bowel compared to conventional 4-field box technique, lowering rates of radiation cystitis, proctitis, and small bowel toxicity. Daily image-guided RT (IGRT) with cone-beam CT (CBCT) ensures millimetric accuracy for pelvic organ motion.

Brachytherapy (Internal Radiation): Administered after EBRT completion as a high-dose-rate (HDR) boost to the primary tumor volume. Intracavitary brachytherapy using vaginal cylinder or ring applicators is used for superficial lesions; interstitial brachytherapy (template-guided perineal implantation with titanium needles using the Martinez Universal Perineal Interstitial Template — MUPIT) is required for bulky or deeply invasive tumors. MRI-guided adaptive brachytherapy (MR-IGBT), following the GEC-ESTRO recommendations, allows personalized dose escalation to the high-risk CTV while constraining doses to the rectum (D2cc <65–70 Gy EQD2) and bladder (D2cc <85–90 Gy EQD2). This approach is available at advanced brachytherapy centers in both India and UAE.

Concurrent Chemotherapy: Weekly cisplatin 40 mg/m² IV (standard radiosensitizer) administered during EBRT, typically 5–6 cycles. Carboplatin AUC 2 weekly substituted for cisplatin in patients with renal impairment or neuropathy.

SYSTEMIC THERAPY (RECURRENT / METASTATIC DISEASE)

Platinum-Based Chemotherapy: Carboplatin AUC 5 + paclitaxel 175 mg/m² every 3 weeks is the preferred first-line doublet for metastatic SCC.

Immunotherapy: Pembrolizumab (anti-PD-1) is approved (FDA Breakthrough, ESMO guideline-supported) for PD-L1-positive (CPS ≥10) or MSI-H/dMMR recurrent/metastatic vaginal cancer based on KEYNOTE-158 data, with an objective response rate of approximately 14–17% and durable responses in biomarker-selected patients. Combination pembrolizumab + chemotherapy is under active investigation.

Targeted Therapy: Bevacizumab (anti-VEGF) may be added to platinum-doublet chemotherapy in recurrent disease by analogy with cervical cancer data (GOG 240 extrapolation), though vaginal-specific randomized data remain limited. Tumor molecular profiling (Foundation One CDx or local NGS panels) is recommended to identify actionable alterations (PIK3CA, KRAS, ERBB2 amplification) for clinical trial eligibility.

FERTILITY PRESERVATION: In carefully selected young patients with Stage I upper-vaginal tumors, fertility-sparing approaches (wide local excision with close follow-up, or radical trachelectomy if the cervix is involved) may be discussed at specialized centers. Ovarian transposition (oophoropexy) prior to pelvic irradiation preserves ovarian function in pre-menopausal women.

STEP 1 — PRE-ARRIVAL CONSULTATION (Weeks 1–2 before travel) Patients submit existing biopsy reports, imaging (MRI/PET-CT), operative notes, and pathology to GAF Healthcare's oncology coordination team. A virtual multidisciplinary tumor board (gynecologic oncologist, radiation oncologist, medical oncologist, radiologist) reviews the case and provides a written treatment recommendation and itemized cost estimate within 48–72 hours. Visa documentation (e-Medical Visa for India; UAE entry visa support) is initiated simultaneously.

STEP 2 — ARRIVAL AND STAGING WORKUP (Days 1–5 in country) Upon arrival, GAF Healthcare's ground team facilitates airport pickup and hotel/hospital guest house check-in. The patient undergoes repeat or supplementary staging: MRI pelvis with gadolinium contrast, PET-CT if not recently performed (within 4 weeks), examination under anesthesia (EUA) with colposcopy, cystoscopy (Stage ≥III), CBC, CMP, GFR, SCC antigen, CA-125, and biomarker profiling (HPV genotype, PD-L1 CPS, MSI/MMR). An anesthesiology pre-assessment is completed for surgical candidates.

STEP 3 — MULTIDISCIPLINARY TUMOR BOARD CONFIRMATION (Day 5–7) All staging data are presented at the institutional tumor board. Final treatment pathway is confirmed (surgery vs. definitive chemoradiation vs. combined approach), and consent is obtained. Radiation planning CT simulation with vaginal fiducial marker insertion is performed for chemoradiation candidates; surgical scheduling is confirmed for operative candidates.

STEP 4A — SURGERY (Day 7–10, if surgical candidate) Robotic-assisted or open radical vaginectomy ± pelvic lymphadenectomy is performed under general anesthesia. Operative time: 2.5–5 hours. ICU observation for 12–24 hours post-operatively. Foley catheter remains in situ for 7–14 days (nerve-sparing technique reduces duration). Pathologic assessment of margins and lymph nodes determines need for adjuvant radiotherapy. Hospital stay: 7–10 days. Drain removal and wound check prior to discharge.

STEP 4B — CONCURRENT CHEMORADIATION (Weeks 1–7, if non-surgical / definitive CRT candidate) EBRT via IMRT/VMAT begins: 25–28 daily fractions (Monday–Friday) over 5–6 weeks. Weekly cisplatin infusion (Day 1, 8, 15, 22, 29, 36) administered in the day-care chemotherapy unit with standard antiemetic prophylaxis (ondansetron + dexamethasone + fosaprepitant). Patients are managed on an outpatient or short-stay basis and monitored weekly for hematologic toxicity (CBC), renal function, and radiation-related mucositis.

STEP 5 — BRACHYTHERAPY BOOST (Weeks 7–9) Following EBRT completion, HDR brachytherapy boost is delivered in 2–5 fractions over 1–2 weeks under sedation or spinal anesthesia. Interstitial template placement (MUPIT) for bulky tumors is performed as a minor surgical procedure with 1–2 night admission. MRI between fractions (adaptive brachytherapy) allows dose optimization.

STEP 6 — RECOVERY AND PRE-DISCHARGE ASSESSMENT (Days 60–70 for CRT; Day 28–42 for surgery) Post-treatment PET-CT or MRI is scheduled 8–12 weeks after completion of definitive therapy to assess treatment response (RECIST 1.1 / PERCIST criteria). Acute toxicity management: vaginal dilator therapy initiated 2–4 weeks after brachytherapy completion to prevent stenosis; pelvic floor physiotherapy; topical estrogen for vaginal mucosal recovery (if not contraindicated). Nutritional and lymphedema assessments completed.

STEP 7 — FIT-TO-FLY CLEARANCE AND DEPARTURE (Weeks 6–10) Surgical patients: cleared for long-haul flight at 4–6 weeks post-operatively if wound healing is complete, no DVT risk factors unmanaged, and no post-surgical complications. CRT patients: cleared at 2–4 weeks after the final brachytherapy fraction, provided acute bowel and bladder toxicity has stabilized to Grade ≤1 (CTCAE v5.0). GAF Healthcare issues a discharge summary, pathology report, treatment summary, and referral letter for the patient's home oncologist. Thromboprophylaxis guidance (low-molecular-weight heparin for flights >6 hours) is provided.

STEP 8 — REMOTE FOLLOW-UP GAF Healthcare coordinates quarterly telemedicine follow-up with the treating gynecologic oncologist for the first 2 years, then semi-annually. Surveillance includes clinical examination, vault smear/cytology, and pelvic MRI every 6 months for 2 years.